In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


bioMerieux, a Family-Owned French Firm, Finally Goes Public

Executive Summary

In early July, the family-owned French firm bioMerieux SA launched an IPO by listing a third of its shares on the French bourse. The offering has been a success, primarily enabling a restless shareholder to sell its stake. And while the microbiology company didn't raise money for itself, it will have to change its corporate culture, opening its books to the public for the first time and requiring it to be responsive to shareholders.

You may also be interested in...

Diagnostic Products Corp.: Thriving, For Now

The popularity of DPC's random-access immunoassay system, the Immulite 2000, has helped the company become a significant player in the highly competitive automated immunoassay market. But DPC's benefited from some good luck--namely the misfortunes of top player Abbott Diagnostics and the slow efforts by other competitors to step into the gap left by Abbott. DPC's dilemma is whether it can maintain its narrow focus as Abbott re-emerges and other competitors get stronger.

How Big Can Bio-Rad Get?

Bio-Rad's having a great year, thanks to its presence in the fast-growing life sciences business of protein analysis, and its surprise success with a test for bovine spongiform encephalopathy (BSE). Founder and CEO David Schwartz built the business based on a mix of eclectic product lines into an $800 million force in life sciences and clinical diagnostics. But as he nears 80, the company is grappling with succession issues, as well as a sense that it needs to better integrate its disparate businesses.

bioMerieux-Pierre Fabre Lives Up to Its Name

Only seven weeks after merging, French diagnostic-pharma company bioMerieux-Pierre Fabre is proposing to buy Organon Teknika's diagnostics business. The deal would combine two players with complementary, not overlapping, strengths in microbiology and infectious diseases. Under Dutch labor law, the proposal must be reviewed by Dutch employee groups and antitrust regulators before Organon Teknika's parent, Akzo Nobel NV, can formally accept it.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts